Skip to content

Absci Corporation ABSI Enterprise value

Enterprise value at other companies

Schrodinger logo
SchrodingerSDGR
$677.89M-44.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$1.04B-39.8%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-$189.23M-1,369%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.1B+100.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%
ADMA Biologics logo
ADMA BiologicsADMA
$2.21B-52.5%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.57B+341%
P/S855.5×+782×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Calculated from Absci Corporation’s reported figures.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Absci Corporation's enterprise value?
Absci Corporation (ABSI) reported enterprise value of $453.38M in Q1 2026.
How has Absci Corporation's enterprise value changed year-over-year?
Absci Corporation's enterprise value increased by 73.1% year-over-year, from $261.86M to $453.38M.
What is the long-term trend for Absci Corporation's enterprise value?
Over 4 years (2021 to 2025), Absci Corporation's enterprise value has grown at a 0.4% compound annual growth rate (CAGR), from $499.72M to $508.15M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.